From Chinese medicine to anticancer drugs

Drug Discovery Today

Volumn 10, Issue 17, 2005, Pages 1131-1132

  Bradbury, Jane ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; E 804; HERBACEOUS AGENT; INDIRUBIN; INDIRUBIN DERIVATIVE; MEISOINDIGO; RETINOIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CHINESE HERB; CHINESE MEDICINE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GASTROINTESTINAL SYMPTOM; HUMAN; INDIGOFERA TINCTORIA; NOTE; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER;

EID: 24944538332     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03587-7     Document Type: Short Survey

References (5)

1. Nam S. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells Proc. Natl. Acad. Sci. U. S. A. 102 2005 5998 6003
2. Xiao Z. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China Leuk. Lymph. 43 2002 1763 1768
3. Jautelat R. From the insoluble dye indirubin to highly active, soluble CDK2 inhibitors ChemBioChem. 6 2005 531 540
4. Hoessel R. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases Nat. Cell Biol. 1 1999 60 67
5. Yu H., Jove R. The STATs of cancer - new molecular targets come of age Nat. Rev. Cancer 4 2004 97 105